What GMP Gap Assessment Services Are
GMP gap assessment services compare your current systems, documents, and practices against the requirements that apply to you. The output is a structured picture of the gaps between current state and required state, ranked by risk. A gap assessment is different from a full audit in emphasis. It is forward looking and focused on readiness, which makes it useful before inspections, before launching a new product, or before integrating an acquired site.
Companies often use gap assessments when they suspect something is missing but are not sure what. The assessment turns that uncertainty into a clear list of issues with a recommended path forward. It is also useful when entering a new market, because requirements differ between regions and what works in one jurisdiction may fall short in another.
A gap assessment is not a box ticking exercise. The best ones challenge assumptions. They ask whether a procedure that exists is actually followed, whether a training program that runs actually produces competence, and whether a validation package that was approved actually supports the process. That level of challenge is what makes the output useful.
The Regulatory Logic Behind Gap Assessments
FDA 21 CFR Parts 210 and 211 as the Baseline
These regulations establish minimum requirements for methods, facilities, and controls used in manufacturing, processing, packing, and holding of drug products. A gap assessment checks whether these fundamentals are in place and working. Specific areas include clean and sanitary buildings free of infestation, equipment surfaces that are not reactive, additive, or absorptive, written cleaning and maintenance procedures, routine calibration and inspection of automated equipment, and data integrity controls under 21 CFR 211.68, 211.180, 211.188, and 211.194.
EU GMP Under EudraLex Volume 4
The EMA coordinates EU requirements through EudraLex Volume 4. Part I covers Basic Requirements for Medicinal Products across Chapters 1 to 9, including Pharmaceutical Quality System, Personnel, Premises and Equipment, Documentation, Production, Quality Control, Outsourced Activities, Complaints and Product Recall, and Self Inspection. Part II covers Active Substances. Annex 1 covers sterile products, Annex 2 covers biological products, Annex 11 covers computerised systems, and Annex 15 covers qualification and validation. A gap assessment maps your current state against each applicable part and annex.
Health Canada GUI-0001
Health Canada regulates GMP through the Food and Drug Regulations and Guidance Document GUI-0001. Requirements address premises, equipment, personnel, sanitation, raw material testing, manufacturing control, quality control, finished product testing, stability testing, and documentation. Specific expectations include medical examination before access to exposed drug areas, API specifications drawn from a pharmacopoeia or equivalent, identity tests on each container of API lot, and uniformity demonstration across at least three consecutive batches.
UK MHRA Orange Guide
The MHRA regulates GMP in the UK through the Orange Guide. Inspections cover Manufacturer’s Licences and Manufacturing Specials licences. Hot topics include Pharmaceutical Quality System compliance, staffing requirements, capacity monitoring, sterility assurance controls, and material transfer controls. Data Integrity guidance requires retained audit trails, no shared or generic user accounts, and demonstrated progress toward system upgrades with individual login and audit trails for legacy automation systems.
WHO GMP Guidelines
The WHO publishes GMP guidelines in the WHO Technical Report Series, compiled in the Quality Assurance of Pharmaceuticals compendium. The 10th edition, Volume 2, covers GMP and Inspection, including main principles, starting materials, specific medical products, water for pharmaceutical use, sampling, quality control laboratories, and HVAC systems for non sterile products. The 2024 to 2027 work plan includes revision of main principles and new guidelines for excipients.
PIC/S Guide PE 009
PIC/S is an international arrangement between regulatory authorities that develops harmonized GMP standards and provides inspector training. The PIC/S Guide PE 009 is used by many authorities as their GMP standard. Part I covers general GMP principles for finished products. Part II covers GMP for active pharmaceutical ingredients and is equivalent to ICH Q7. Annex 1 was revised effective August 2023, with Section 8.123 for lyophilisers effective August 2024.
ICH Q9 and ICH Q10
ICH Q9 asks companies to manage quality risk in a structured way, and ICH Q10 ties audit results to management review and continual improvement. Gap findings are scored by risk so remediation addresses the most serious gaps first. Risk scoring also gives management a defensible basis for budget decisions.
How Our GMP Gap Assessments Work
Scope Definition and Document Review
We start by agreeing on scope. Which products, which sites, which regulations. Then we review your documentation against the requirements. This phase often reveals issues before we even visit the site.
On Site or Remote Verification
Documents tell only part of the story. We verify practices on site or through remote sessions to confirm that what is written matches what happens. We interview staff at different levels and observe operations.
Gap Identification and Risk Scoring
Each gap is described clearly, linked to the relevant requirement, and scored for risk. That scoring helps you decide what to fix first. We separate critical gaps from minor ones so the priorities are obvious.
Prioritized Remediation Roadmap
We deliver a roadmap that sequences the work, estimates effort, and identifies quick wins alongside longer term projects. The roadmap is practical and designed to fit within your resource constraints.
Optional Follow Up
We can return after remediation to confirm that gaps have been closed. This gives you a clean record and confidence before an inspection.
Typical Gaps We Uncover
Missing or Outdated SOPs
Procedures that have not kept pace with current practice or regulations are a common finding. Sometimes the procedure is fine but the practice has drifted. Either way, the gap matters.
Undefined Roles and Responsibilities
When nobody owns a task, it tends not to get done. We identify unclear ownership and recommend fixes. Clear ownership is one of the simplest and most effective improvements a company can make.
Incomplete Validation Documentation
Validation packages with missing elements, such as cleaning validation or analytical method transfers, are frequently uncovered. These gaps can delay product launches and raise questions during inspections.
Weak Data Integrity Controls
Audit trails, access controls, and electronic record management are common gap areas, especially in older systems. Health Canada and MHRA both place heavy emphasis on data integrity, and legacy automation systems are a frequent weak point.
Training Program Weaknesses
Training that is completed but not effective is a hidden gap. We check whether training content matches current procedures and whether competence is assessed.
Supplier Oversight Gaps
Oversight that relies only on certificates and questionnaires is a common gap. We help companies build a risk based oversight program that holds up to scrutiny.
When a Gap Assessment Makes Sense
Before an Inspection
A gap assessment before an inspection surfaces issues while there is still time to fix them.
Before a Product Launch
New products bring new requirements. A gap assessment checks readiness before the first batch is released.
After an Acquisition
Acquired sites often have different systems. A gap assessment shows what needs to change to meet your standards and the regulator’s expectations.
Before Entering a New Market
Requirements differ between regions. A gap assessment maps the differences and the work needed.
Introducing GxP Cellators for GMP Auditing Services
GxP Cellators is a global GMP auditing provider with presence in Saskatchewan, Calgary, and Toronto in Canada, North Carolina and Indiana in the United States, and Frankfurt in Germany. Our auditors walk your floors, review batch records, and trace deviation history to find gaps before inspectors do. We work across the full range of regulatory frameworks, including US FDA 21 CFR Parts 210 and 211, EU EMA EudraLex Volume 4, Health Canada GUI-0001, UK MHRA Orange Guide, WHO Technical Report Series, and PIC/S Guide PE 009.
Our GMP auditing services cover sterile manufacturing facilities, non sterile manufacturing facilities, contract manufacturing organizations, quality systems and validation, and batch release and inspection readiness. We provide internal GMP audits, supplier and vendor audits, CMO audits, pre approval inspection readiness audits, for cause audits, follow up and CAPA verification audits, and mock regulatory inspections. Our process runs from planning and opening meeting through fieldwork, closing meeting, reporting, and follow up, with clear outputs at every stage.
For gap assessments specifically, our auditors evaluate cleanroom design and classification, air flow patterns, personnel and material flows, environmental monitoring programs, aseptic technique, media fill design and execution, sterilization validation, isolator integrity, container closure integrity, cleaning validation based on worst case conditions with toxicological data, changeover procedures, process validation, continued process verification, water system design and monitoring, documentation control, deviation investigation depth, CAPA effectiveness, change control impact assessment, training effectiveness, self inspection scope, supplier qualification, validation DQ, IQ, OQ, and PQ, and data integrity controls aligned with ALCOA plus principles.
Start Your GMP Gap Assessment
See our GMP Auditing page at https://www.gxpcellators.com/gmp-auditing/ for more detail. Email or use https://www.gxpcellators.com/contact/ to request a scoping call.
Frequently Asked Questions About GMP Gap Assessments
When should we request a gap assessment?
Common triggers include preparing for an inspection, launching a new product, integrating an acquired site, or moving to a new market with different regulatory requirements. Any major change is a good time to check your footing.
How is a gap assessment different from a mock inspection?
A mock inspection simulates a regulatory inspection and focuses on how you would perform under scrutiny. A gap assessment is broader and compares your whole system against requirements, often with a readiness roadmap. The two can be combined.
Do you provide a remediation plan?
Yes. Each gap is linked to a recommended action and ranked by risk. The roadmap sequences the work so you can plan resources realistically and show progress to management.
Can a gap assessment cover multiple sites?
Yes. Multi site assessments are common for companies that want a consistent view across their network. We use a common framework and adapt to each site, which makes comparison easier.
How long does a gap assessment take?
It depends on scope. A single site focused assessment may take one to two weeks. A multi site program takes longer and is usually phased.
Will the assessment disrupt production?
We plan around your schedule and keep disruption low. Most of the work is document review and interviews, with limited time on the floor.
Do you assess against more than one regulatory framework?
Yes. We assess against FDA, EMA, Health Canada, MHRA, WHO, and PIC/S frameworks in a single engagement. This is useful for companies with global ambitions.
How do I book a gap assessment?
Email or use https://www.gxpcellators.com/contact/. Service details are at https://www.gxpcellators.com/gmp-auditing/.
